Illumina, Inc. logo

Illumina, Inc. (ILMN)

Market Closed
21 Jul, 18:11
NASDAQ (NGS) NASDAQ (NGS)
$
96. 05
-0.09
-0.09%
$
15.6B Market Cap
- P/E Ratio
0% Div Yield
222,204 Volume
0.66 Eps
$ 96.14
Previous Close
Day Range
92.3 96.3
Year Range
68.7 156.66
Want to track ILMN and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 10 days
China bans imports of Illumina's gene sequencers

China bans imports of Illumina's gene sequencers

China announced a ban on Tuesday on imports of genetic sequencers from U.S. medical equipment maker Illumina , just minutes after U.S. President Donald Trump's additional 10% tariff on Chinese goods took effect.

Reuters | 4 months ago
Here's Why Illumina (ILMN) is a Strong Value Stock

Here's Why Illumina (ILMN) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks | 4 months ago
Illumina, Inc. (ILMN) AGBT Investor Session Conference (Transcript)

Illumina, Inc. (ILMN) AGBT Investor Session Conference (Transcript)

Illumina, Inc. (NASDAQ:ILMN ) AGBT Investor Session Conference February 25, 2025 11:00 AM ET Company Participants Salli Schwartz - Head of Investor Relations Jacob Thaysen - Chief Executive Officer Steve Barnard - Chief Technology Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Subbu Nambi - Guggenheim Securities Dan Brennan - TD Cowen Dan Arias - Stifel Puneet Souda - SVB Securities Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies LLC Patrick Donnelly - Citi Tejas Savant - Morgan Stanley Jack Meehan - Nephron Research Kyle Mikson - Canaccord Genuity Salli Schwartz Welcome. Thank you for your patience while we got started.

Seekingalpha | 4 months ago
ILMN Stock Might Rise From Collaboration With Broad Clinical Labs

ILMN Stock Might Rise From Collaboration With Broad Clinical Labs

Illumina Collaborates with Broad Clinical Labs to set the standard for scalable single-cell research and accelerate discovery in areas such as disease modeling and drug development.

Zacks | 4 months ago
Here's Why Illumina (ILMN) is a Strong Growth Stock

Here's Why Illumina (ILMN) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 5 months ago
ILMN vs. ALNY: Which Stock Is the Better Value Option?

ILMN vs. ALNY: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Illumina (ILMN) and Alnylam Pharmaceuticals (ALNY). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks | 5 months ago
Why Illumina (ILMN) is a Top Value Stock for the Long-Term

Why Illumina (ILMN) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 5 months ago
Why Illumina Stock Got Mashed on Monday

Why Illumina Stock Got Mashed on Monday

On Monday, for the second time in as many business days, Illumina (ILMN -5.47%) stock took it on the chin because of an analyst recommendation downgrade. The biotech's shares closed the day almost 6% lower, during a session when the S&P 500 (^GSPC 0.67%) landed in the black with a 0.7% increase.

Fool | 5 months ago
Illumina (ILMN) International Revenue Performance Explored

Illumina (ILMN) International Revenue Performance Explored

Review Illumina's (ILMN) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Zacks | 5 months ago
Illumina: Regulatory Risk In China And Weaker Sales Rebound Mask A Solid Rebound Of Its Profitability

Illumina: Regulatory Risk In China And Weaker Sales Rebound Mask A Solid Rebound Of Its Profitability

Illumina restored its profitability well: Free Cash Flow is reaching elevated levels. However, the placement of ILMN in China's unreliable entity list could have disruptive implications for its operations in the country. The maximum exposure is 7% of its sales, which is manageable.

Seekingalpha | 5 months ago
Why Illumina Stock Is Sinking Today

Why Illumina Stock Is Sinking Today

Shares of Illumina (ILMN -8.97%) were falling on Friday. The company's stock was down by as much as 11.4% early in the session, and was still off by 8.7% as of 2:38 p.m.

Fool | 5 months ago
Illumina Analysts Slash Their Forecasts Following Q4 Results

Illumina Analysts Slash Their Forecasts Following Q4 Results

Illumina, Inc. ILMN reported better-than-expected results for its fourth quarter on Thursday.

Benzinga | 5 months ago
Loading...
Load More